USA flag logo/image

An Official Website of the United States Government

Sequence Identification of Wound Infection with Celadon Clinical Software

Award Information

Agency:
Department of Defense
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
O112-H16-3039
Solicitation Year:
2011
Solicitation Topic Code:
OSD11-H16
Solicitation Number:
2011.2
Small Business Information
Celadon Laboratories, Inc.
6525 Belcrest Rd Suite 521 Hyattsville, MD -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Sequence Identification of Wound Infection with Celadon Clinical Software
Agency: DOD
Contract: W81XWH-12-C-0062
Award Amount: $149,967.00
 

Abstract:

Infection with Acinetobacter baumanni, especially drug-resistant strains, is a serious threat to U.S. military personnel and to the U.S. population. Identification of wound pathogens and their drug susceptibility within minutes to hours, and administration of the appropriate drug, could significantly increase soldier and patient survival. Celadon and its consultants propose to: 1) Finalize 16S rRNA primer-directed amplification; 2) Select from the literature, or develop, primers to execute the amplification strategy; 3) Apply the strategy to 80 Acinetobacter baumanni strains at different concentration levels; 4) Compare PacBio RS to the most promising desk-top instrument; 5) Demonstrate prototype extension of Celadon Clinical software to sequence identification of wound pathogens. Microbiome consultants on this project are David A. Rasko, Ph.D. and Lynne M. Schriml, Ph.D., both of the Institute for Genome Sciences, University of Maryland School of Medicine. Nathan J. Edwards, Ph.D., of Georgetown Medical Center, Georgetown University, Washington, DC is consulting on selection of unique sequences. Michael J. Bosse, M.D., Principal Investigator of the DoD-funded BioBurden Study, will collect wound samples. The end result will be a substantial contribution to the development of a sequence-based test will provide the clinician with the information necessary to select the most appropriate antibiotic.

Principal Investigator:

Raymond J. Peterson, Ph.D.
Chief Science Officer
(301) 683-2118
peterson@celadonlabs.com

Business Contact:

Lawrence A. Kessner
Chief Executive Officer
(301) 683-2117
lkessner@celadonlabs.com
Small Business Information at Submission:

Celadon Laboratories, Inc.
6525 Belcrest Rd Suite 521 Hyattsville, MD -

EIN/Tax ID: 522223222
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: Yes